BridgeBio Pharma: Unrivaled Heart Medication Generates Record Revenues
Reading Time: 3 minutes
Genetic disorders are generally considered rare diseases, but when they do occur, they are usually associated with significant limitations on quality of life and life expectancy. Typically, these include hereditary heart diseases or cancers triggered by genetic mutations. A license obtained in November 2024 makes BridgeBio a significant player with great potential in this field. In the last 20 days, the stock price of the biopharmaceutical company has risen by about 37%. In November 2024, BridgeBio received a groundbreaking FDA approval for the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
